Microsphere Delivery of Antisense Oligonucleotides for Autoimmune Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acids, such as antisense oligonucleotides, face challenges including low loading efficiency, toxicity, and immune stimulation, particularly in the context of treating autoimmune diabetes, where existing polymers like PLGA can stimulate the immune system and result in adverse responses.
Innovation Solution
The development of microspheres fabricated using aqueous conditions, incorporating antisense oligonucleotides targeted to CD40, CD80, and CD86 transcripts, which are designed to inhibit gene expression and induce dendritic cell tolerance, thereby preventing and reversing autoimmune diabetes in NOD mice.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polymers like PLGA are used for microsphere fabrication, then the structural integrity and drug delivery capability are improved, but immune system stimulation and adverse responses occur
Solution Approach 1:
The patent extracts and removes the problematic PLGA polymer component from the microsphere formulation, replacing it with alternative materials that do not stimulate the immune system. This eliminates the harmful immune response while preserving the microsphere's drug delivery function.
Solution Approach 2:
The patent employs composite material formulations that combine biocompatible polymers with specific surface coatings or modifications. These composite materials maintain the structural integrity needed for drug delivery while eliminating immune stimulation through careful material selection and composition.
2Reliability
If substantial quantities of microspheres are administered to achieve therapeutic effect, then the therapeutic efficacy is improved, but the dosage complexity and potential toxicity increase
Solution Approach 1:
The patent changes the physical and chemical parameters of the microsphere formulation, including particle size distribution, polymer composition, and drug loading concentration. These parameter optimizations enable achieving therapeutic effects with reduced dosages, minimizing toxicity and administration complexity.
3Reliability
If nucleic acids are delivered directly to animals, then the therapeutic potential is improved, but nucleic acid degradation by endogenous nucleases occurs
Solution Approach 1:
The patent introduces microspheres as an intermediary delivery vehicle that protects nucleic acids from degradation by endogenous nucleases. The microsphere matrix acts as a protective barrier, allowing nucleic acids to reach target cells intact while maintaining their therapeutic potential.
Solution Approach 2:
The patent utilizes the microsphere shell structure to encapsulate and protect nucleic acids. This flexible protective shell prevents nuclease access while allowing cellular uptake, thereby maintaining nucleic acid stability during in vivo delivery.
4Productivity
If viral vectors are used for nucleic acid delivery, then the delivery efficiency is improved, but severe adverse and fatal immune responses occur
Solution Approach 1:
The patent replaces persistent viral vectors with biodegradable polymer microspheres that fulfill their delivery function and then degrade harmlessly. These temporary delivery vehicles achieve sufficient nucleic acid delivery efficiency without causing the severe immune responses associated with viral vectors.
Solution Approach 2:
The patent converts the potential harm of immune system activation into a benefit by using biodegradable materials that trigger minimal immune response compared to viral vectors. The controlled degradation products of the polymer microspheres are naturally processed by the body, transforming a potential harmful interaction into a safe and effective delivery system.
Data Source
AI summary
AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.